These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33390149)

  • 1. Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature.
    Ma Z; Li H; Liu L
    Recent Pat Anticancer Drug Discov; 2021; 16(1):101-107. PubMed ID: 33390149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
    Huang M; Huang B; Li G; Zeng S
    BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
    Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
    Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.
    Zhang J; Wu L; Liu J; Lin M
    Immunotherapy; 2020 Jun; 12(8):555-561. PubMed ID: 32372672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
    Wang Z; Zeng T; Li Y; Zhang D; Yuan Z; Huang M; Yang Y; Zhou W
    Front Immunol; 2021; 12():799822. PubMed ID: 35003124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocarcinoma: investigations into pathway-targeted therapies.
    Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].
    Kudoh K; Doi K; Ohchi T; Ogata K; Matsuo A; Ohtao R; Sugimura H; Muranaka T
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):1993-5. PubMed ID: 18219876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
    Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
    Gao F; Yang C
    Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
    Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Sporadic Case of Advanced Metastatic Cholangiocarcinoma in a Child: A Case Report and Review of Literature.
    Hall C; Mamlok V; Al-Khalil I
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e333-5. PubMed ID: 25851556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report.
    Ryu J; Lee K; Joe C; Joo J; Lee N; Yoo HS
    Integr Cancer Ther; 2018 Jun; 17(2):558-561. PubMed ID: 28745084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
    Shroff RT; Yarchoan M; O'Connor A; Gallagher D; Zahurak ML; Rosner G; Ohaji C; Sartorius-Mergenthaler S; Parkinson R; Subbiah V; Zinner R; Azad NS
    Br J Cancer; 2017 May; 116(11):1402-1407. PubMed ID: 28441383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
    Huang TW; Wang CH; Hsieh CB
    Onkologie; 2007 Mar; 30(3):129-31. PubMed ID: 17341899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
    Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
    J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.